Trial Profile

A Study Analyzing Risk for Myocardial Infarction, Stroke, and Pulmonary Embolism Following COVID-19 Vaccines

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 27 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Ad26.COV2 S (Primary) ; AZD 1222 (Primary) ; Elasomeran (Primary) ; Tozinameran (Primary)
Indications COVID 2019 infections
Focus Adverse reactions

Most Recent Events

28 Aug 2022 Results assessing the Risk of Myocardial Infarction, Stroke, and Pulmonary Embolism Following Different COVID-19 Vaccines in Adults Under 75 Years of Age in France is presented at the 38th International Conference on Pharmacoepidemiology and Therapeutic Risk Management
25 Aug 2022 New trial record
23 Aug 2022 Results published in the Annals of Internal Medicine

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com